.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Novartis
Teva
Mallinckrodt
Queensland Health
Baxter
Johnson and Johnson
Express Scripts
Dow

Generated: December 13, 2017

DrugPatentWatch Database Preview

Pralatrexate - Generic Drug Details

« Back to Dashboard

What are the generic sources for pralatrexate and what is the scope of pralatrexate freedom to operate?

Pralatrexate
is the generic ingredient in one branded drug marketed by Allos and is included in one NDA. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Pralatrexate has forty-two patent family members in twenty-one countries.

There are two drug master file entries for pralatrexate. One supplier is listed for this compound. There is one tentative approval for this compound.

Pharmacology for pralatrexate

Tentative approvals for PRALATREXATE

Applicant Application No. Strength Dosage Form
u► Subscribe20MG/1MLINJECTABLE;INJECTION
u► Subscribe40MG/2MLINJECTABLE;INJECTION
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
AllosFOLOTYNpralatrexateSOLUTION;INTRAVENOUS022468-002Sep 24, 2009RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
AllosFOLOTYNpralatrexateSOLUTION;INTRAVENOUS022468-002Sep 24, 2009RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllosFOLOTYNpralatrexateSOLUTION;INTRAVENOUS022468-002Sep 24, 2009RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllosFOLOTYNpralatrexateSOLUTION;INTRAVENOUS022468-001Sep 24, 2009RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AllosFOLOTYNpralatrexateSOLUTION;INTRAVENOUS022468-001Sep 24, 2009RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AllosFOLOTYNpralatrexateSOLUTION;INTRAVENOUS022468-002Sep 24, 2009RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllosFOLOTYNpralatrexateSOLUTION;INTRAVENOUS022468-001Sep 24, 2009RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
AllosFOLOTYNpralatrexateSOLUTION;INTRAVENOUS022468-001Sep 24, 2009RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: pralatrexate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,323,205 Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors► Subscribe
7,939,530Treatment of lymphoma using 10-propargyl-10-deazaaminopterin and gemcitabine► Subscribe
8,263,354Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin► Subscribe
8,168,404Methods to treat cancer with 10-propargyl-10-deazaaminopterin and methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: pralatrexate

Country Document Number Estimated Expiration
Australia2005249516► Subscribe
Norway337276► Subscribe
Slovenia1750716► Subscribe
Portugal1750716► Subscribe
Denmark1750716► Subscribe
European Patent Office1750716► Subscribe
CroatiaP20080569► Subscribe
Norway20065971► Subscribe
Denmark0944389► Subscribe
South Korea20070035490► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Novartis
Express Scripts
McKinsey
McKesson
Julphar
UBS
Moodys
Teva
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot